Saltar al contenido

Regeneron Pharmaceuticals, Inc. (REGN) stock: revenue, earnings & dividend

Regeneron Pharmaceuticals, Inc. (REGN, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener REGN · Nasdaq Pharma & Biotech US-NY

Key figures

Fiscal year
2025
Revenue
14.3 bn $
Revenue growth
1 %
Revenue growth 5y (p.a.)
11 %
Net income
4.5 bn $
Net margin
31.4 %
Operating margin
25 %
Earnings per share (diluted)
41.48 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
40.6 bn $
Equity
31.3 bn $
Equity ratio
77.1 %
Return on equity
14.4 %
Cash
3.12 bn $
Operating cash flow
4.98 bn $
Free cash flow
–
Shares outstanding
–

History

Revenue by fiscal year

2016 4.86 bn $
2017 5.87 bn $
2018 5.15 bn $
2019 6.56 bn $
2020 8.5 bn $
2021 16.1 bn $
2022 12.2 bn $
2023 13.1 bn $
2024 14.2 bn $
2025 14.3 bn $

Net income by fiscal year

2016 896 m $
2017 1.2 bn $
2018 2.44 bn $
2019 2.12 bn $
2020 3.51 bn $
2021 8.08 bn $
2022 4.34 bn $
2023 3.95 bn $
2024 4.41 bn $
2025 4.5 bn $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
202514.3 bn $4.5 bn $41.48 $–4.98 bn $
202414.2 bn $4.41 bn $38.34 $–4.42 bn $
202313.1 bn $3.95 bn $34.77 $–4.59 bn $
202212.2 bn $4.34 bn $38.22 $–5.01 bn $
202116.1 bn $8.08 bn $71.97 $–7.08 bn $
20208.5 bn $3.51 bn $30.52 $–2.62 bn $
20196.56 bn $2.12 bn $18.46 $–2.43 bn $
20185.15 bn $2.44 bn $21.29 $–2.2 bn $
20175.87 bn $1.2 bn $10.34 $–1.31 bn $
20164.86 bn $896 m $7.70 $–1.49 bn $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)